Scarica l'app Stockscreener
1.27
4.10%
0.05
Dopo l'orario di chiusura:
1.31
0.04
+3.15%
Nexalin Technology Inc Borsa (NXL) Ultime notizie
Nexalin Technology slides after pricing $5M stock offering - MSN
Nexalin Technology, Inc. Closes Public Offering of 3,850,000 Shares at $1.30 Per Share, Raising $5.0 Million - Nasdaq
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering - GlobeNewswire
Brain Tech Pioneer Nexalin Secures $5M Funding: 3.85M Shares at $1.30 in Public Offering - Stock Titan
Nexalin Technology Announces Public Offering Agreement - TipRanks
Form 424B4 Nexalin Technology, Inc. - StreetInsider
Nexalin Gains International Traction - ACCESS Newswire
Nexalin Shares Fall After Pricing of $5 Million Public Offering - marketscreener.com
Nexalin Technology (NXL) Announces Public Stock Offering | NXL S - GuruFocus
Nexalin Technology sets public offering at $1.30 per share - Investing.com Australia
Nexalin Prices 3.85 Mln Public Offering At $1.30/shr; Stock Plunges In Pre-market - Nasdaq
Nexalin Technology sets public offering at $1.30 per share By Investing.com - Investing.com India
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock - GlobeNewswire
Nexalin Technology Prices $5 Million Public Offering - marketscreener.com
$5M Public Offering: How Nexalin Plans to Advance Revolutionary Brain Stimulation Technology - Stock Titan
SEC Form 424B5 filed by Nexalin Technology Inc. - Quantisnow
Nexalin Technology, Inc. (NASDAQ:NXL) Shares Acquired by Geode Capital Management LLC - Defense World
SEC Form 424B4 filed by Nexalin Technology Inc. - Quantisnow
Nexalin Technology (NXL) Seeks FDA Feedback for Gen-2 SYNC Syste - GuruFocus
Nexalin Technology Says Q-Submission To Facilitate Dialogue With FDA On Clinical Trial Design - marketscreener.com
Nexalin Technology, Inc. Plans Q-Submission to FDA for Gen-2 SYNC System Targeting Cognitive Disorders - Nasdaq
Nexalin Technology Initiates FDA Q-Submission Process for - GlobeNewswire
FDA Fast-Tracks Nexalin Gen-2 SYNC Review for Alzheimer's Treatment | NXL Stock News - Stock Titan
Nexalin Technology (NASDAQ:NXL) Shares Down 0.5% – Time to Sell? - Defense World
International Milestone for Anxiety-Insomnia Neurostim Company - Sleep Review
Nexalin Technology files $50M common stock offering - MSN
Nexalin Technology (NXL) Gains Approval for Clinical Trial in Br - GuruFocus
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia - GlobeNewswire
Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And Insomnia - marketscreener.com
Nexalin's Neurostimulation Device Begins Phase II Trial for Anxiety and Insomnia Treatment in Brazil - Stock Titan
Nexalin Technology Inc May Offer, Sell Up To $50 Mln Of Common Stock From Time To Time In One Or More Offerings - marketscreener.com
Nexalin Technology (NXL) Launches Advanced Virtual Clinic for Mi - GuruFocus
Nexalin Technology Announces Launch of Virtual Clinic to Enhance Clinical Research and Patient Care for Mental Health Disorders - Nasdaq
Nexalin Technology Announces Completion of Phases One - GlobeNewswire
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management - TradingView
Nexalin Technology, Inc. Supports Health Tech Investment Act to Enhance Medicare Reimbursement for AI-Enabled Medical Devices - Nasdaq
Nexalin Technology Expresses Strong Support for Health Tech - GlobeNewswire
Medicare May Cover AI Mental Health Devices as Nexalin Backs New Bill | NXL Stock News - Stock Titan
Nexalin Technology appoints new accounting firm By Investing.com - Investing.com Canada
Nexalin Technology appoints new accounting firm - Investing.com
Nexalin secures patent on brain stimulation method for substance use disorders - Yahoo
Nexalin Secures Patent for Intracranial Stimulation Technology - marketscreener.com
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders - The Manila Times
Nexalin Technology Secures USPTO Patent for Deep - GlobeNewswire
Game-Changing Patent: Nexalin's Brain Stimulation Tech Takes On $35B Addiction Treatment Market - Stock Titan
Nexalin begins clinical trial for brain stimulation therapy By Investing.com - Investing.com South Africa
Nexalin begins clinical trial for brain stimulation therapy - Investing.com
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial - The Manila Times
Revolutionary Brain Treatment: Nexalin Launches PTSD Trial at UCSD with AI-Powered Home Therapy - Stock Titan
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3 - GlobeNewswire
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3 - The Manila Times
Revolutionary Brain Tech Targets $537B Market: Nexalin CEO Reveals Growth Strategy - Stock Titan
Nexalin Technology (NASDAQ:NXL) Upgraded at Maxim Group - The AM Reporter
Nexalin Technology (NASDAQ:NXL) Upgraded to “Buy” at Maxim Group - Defense World
Maxim Group Upgrades Nexalin Technology (NXL) - Nasdaq
Nexalin Technology, Inc. SEC 10-K Report - TradingView
0.11%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):